The Food and Drug Administration today awarded a contract to the National Academies of Sciences, Engineering, and Medicine to develop evidence-based guidelines for appropriate opioid analgesic prescribing for acute pain resulting from specific conditions or procedures. FDA Commissioner Scott Gottlieb, M.D., said the “primary scope of this work is to understand what evidence is needed to ensure that all current and future clinical practice guidelines for opioid analgesic prescribing are sufficient, and what research is needed to generate that evidence in a practical and feasible manner.” FDA said this work would build on efforts started by the Centers for Disease Control and Prevention to develop federal guidelines on pain management and the use of opioids, but the guidelines FDA develops “would be based on prospectively gathered evidence drawn from evaluations of clinical practice and the treatment of pain.” In addition, Gottlieb said this work could potentially inform drug labelling. As part of the contract, NASEM will conduct a study and issue a report on its findings.

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.